Pemvidutide
A balanced GLP-1 and glucagon dual agonist from Altimmune with obesity and liver-disease relevance.
Also referenced as: ALT-801
Also appears in: Hormone
This compound has a genuine development or study trail, but it is not an approved routine drug.
Primary lane: Weight Loss. Also surfaces under Hormone for browsing and discovery.
ALT-801
No FDA label signal · 15 trials · 15 PubMed results
What pemvidutide is
Pemvidutide is an investigational GLP-1 / glucagon dual receptor agonist from Altimmune being developed for obesity and serious liver-disease indications.
Why it matters
Unlike some obesity candidates that are trying only to win the body-weight leaderboard, pemvidutide is increasingly important because of its MASH / liver-disease positioning and FDA Breakthrough Therapy status in that area.
Regulatory context
Pemvidutide is not FDA approved. It remains an investigational asset, but it is already one of the more visible dual-agonist names in liver-metabolic development.
Practical reading note
This is a good example of a peptide candidate whose strategic value may come as much from liver disease as from obesity itself.